£45.9M
British Patient Capital joins existing backers including Visa to fund product development and market expansion.
British Patient Capital
GovernmentBritish Patient Capital operates a £375m programme called Future Fund: Breakthrough, co-investing with private sector investors in R&D-intensive UK companies.
Recent investments
£17.5M
The round was backed by British Patient Capital, Lombard Odier Investment Managers, and Northzone to help scale services for frontline employees.
"Do frontline workers not deserve choice? Do frontline workers – who keep essential services running in good times and tough times – not deserve a better financial future?"
$42.0M
The equity round was led by EQT Life Sciences and Sectoral to support international expansion and clinical trials.
"Dysphagia is a severe medical condition that affects countless patients in hospital. It can increase hospital length of stay, the risk of complications, and lengthens recovery time. The Phagenyx System demonstrates significant reductions in hospital length of stay, with a corresponding and substantial reduction in healthcare costs, as evidenced by the Company’s strong portfolio of high-quality clinical studies. This is strongly aligned with EQT’s Health Economics strategy of transforming cutting-edge scientific innovation into impactful and cost-effective healthcare solutions. We‘re excited to support the next phase of Phagenesis’ journey."
£40.5M
Pfizer Ventures led the financing round alongside Columbus Venture Partners and British Patient Capital.
"This financing will enable us to expand our team, progress our lead assets into the clinic and expand our drug discovery platform. We welcome our new investors alongside our existing strong syndicate and look forward to working together to take Curve to its next stage of growth."
£162M
The largest European semiconductor venture funding round to date will support the construction of new fabrication lines in the UK.
"This successful Series D round is a clear testament to the massive opportunity for our innovative technology to enable item-level intelligence in virtually any object on the planet. Our global customers value our ultra-thin and flexible form factor, our breakthrough low cost of customisation and rapid production cycles, as well as the lower environmental footprint compared to silicon. Scaling our manufacturing capacity on the UK’s first ever 300mm wafer production lines at our site in Durham will enable us to deliver hundreds of billions of chips to customers worldwide over the coming decade."